metastatic head and neck cancer Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 2 (1)

Interventional (1)

Adaptimmune (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadmetastatic head and neck cancer

I am/have/hadneck cancer

I am/have/hadcarcinoma

I am/have/hadHIV Infection

I am/have/hadpd-l1

I am/have/hadrecurrent disease

I am/have/hadchemotherapy regimen

I am/have/hadmetastatic head and neck carcinoma

I am/have/hadmeasurable disease

I am/have/hadmetastasis

I am/have/hadcancer

I am/have/hadejection fraction

I am/have/hadsquamous cell carcinoma

I am/have/hadhead and neck cancer

I am/have/hadmonoclonal antibody therapy

I am/have/hadimmunodeficiency

I am/have/hadcns metastases

I am/have/hadhepatitis b

I am/have/hadsquamous cell carcinoma of head and neck

added new label for I am/have/had

more

I am looking for

I am looking forcyclophosphamide

I am looking formonoclonal antibodies

I am looking forhepatitis b

I am looking forpembrolizumab

I am looking forfludarabine

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.

monoclonal antibodies

metastatic head and neck cancer

neck cancer

HIV Infection

carcinoma

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.